Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.
Galecto, a US-based fibrosis and cancer therapy developer advancing research originating from Lund and Edinburgh universities, has filed to raise up to $100m initial public offering.
Founded in 2011 in Sweden, Galecto is working on small molecule therapeutics for diseases such as cancer and fibrosis, a condition where connective tissue becomes scarred.
The IPO proceeds will fund development of the company’s lead product candidate, GB0139, with some cash going to a phase 3 clinical trial in idiopathic…
